STOCK TITAN

Twist Bioscience Corp - TWST STOCK NEWS

Welcome to our dedicated news page for Twist Bioscience (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Twist Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Twist Bioscience's position in the market.

Rhea-AI Summary
Twist Bioscience (NASDAQ: TWST) launches a new Human Pangenome Spike-in for the Twist Exome 2.0 panel to enhance genetic variation detection during whole exome sequencing. The tool aims to provide a more comprehensive view of human genetic diversity, leveraging the Human Pangenome Reference Consortium's diverse genomic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces CE-marked Precision Dx Products compliant with EU IVDR regulations, including Twist Precision Prep and Enrichment Dx Kit, Twist Precision Exome Dx Panel, and Twist Precision Exome Dx Kit. The products aim to facilitate panel sequencing within clinical settings, meeting high quality standards. Twist collaborates with Platomics to streamline documentation generation and regulatory compliance. CEO Emily M. Leproust highlights the significance of IVDR certification for diagnostic tests and the company's commitment to supporting European customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) executives will participate in fireside chats at upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. The chats will be webcast live and available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 122,400 restricted stock units (RSUs) to 36 recently hired individuals as an employment inducement. The RSUs vest over a 48-month period, with 25% vesting on the one year anniversary of the start date of the employee, and 1/16 of the RSUs vesting on each quarterly anniversary thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) and Element Biosciences, Inc. announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. The collaboration aims to offer customers an economical and streamlined approach to next generation sequencing. The Exome 2.0 panel and high performing library preparation and target enrichment reagents are designed to provide best-in-class sequencing, detect rare and inherited diseases, and germline cancers. The purpose-built solution for Element’s AVITI chemistry will reduce per sample sequencing requirements, potentially saving downstream sequencing costs. The companies have ambitious product roadmaps for 2024 to make sequencing even easier for labs to produce the highest quality data at a low cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) has launched the cfDNA Library Preparation Kit to enable liquid biopsy research, addressing challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input. The kit can detect rare allele variants due to its high conversion rate and protocols minimize sample handling for a streamlined workflow and results delivered within two hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced the early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit, a novel technology that aims to enable unparalleled throughput at a fraction of the cost of existing on-market solutions. The kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology, crucial for researchers in AgBio who sequence thousands of samples of varying inputs. The technology is positioned to drive NGS adoption in agricultural genomics, enabling streamlined, scalable, and cost-effective workflows for high-throughput applications in breeding, trait selection, and other research areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $71.5M in 1QFY24, a 32% increase over 1QFY23. Orders increased to $77.5M, a 19% increase over 1QFY23. The company raised its FY 2024 revenue guidance to $288M to $293M and increased FY 2024 gross margin guidance to 40% to 41%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.01%
Tags
earnings
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its Twist Express Genes service to include larger DNA preparations, offering rapid gene synthesis at all gene prep scales, enabling large scale experimentation for pharmaceutical, biotechnology, academic, and industrial chemical researchers. The service has received positive feedback from customers for its consistent and rapid turnaround time. The company leverages its silicon-based DNA synthesis platform to deliver Clonal Genes and Gene Fragments at scale and with rapid turnaround times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will issue its financial results for the fiscal 2024 first quarter on February 2, 2024. The company plans to hold a conference call and live audio webcast to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website. The conference call will be webcast live and the webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences earnings
Twist Bioscience Corp

Nasdaq:TWST

TWST Rankings

TWST Stock Data

1.98B
56.96M
1.79%
113.08%
20.78%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About TWST

at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .